By Professor Michelle Haber

Book Chapters

Xu N; Tse B; Yang L; Tang TCY; Haber M; Micklethwaite K; Dolnikov A, 2022, 'Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy: A Recent Study', in Current Innovations in Medicine and Medical Science Vol. 3, Book Publisher International (a part of SCIENCEDOMAIN International), pp. 61 - 87, http://dx.doi.org/10.9734/bpi/cimms/v3/7736f

Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA, 2021, 'Cell-based methods for the identification of Myc-inhibitory small molecules', in The Myc Gene: Methods and Protocols, pp. 337 - 346, http://dx.doi.org/10.1007/978-1-0716-1476-1_19

Fletcher J; Roundhill E; Haber M; Norris M, 2014, 'Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis', in Efferth T; Bonavida B (ed.), Resistancce to Targeted Anti-Cancer Therapeutics, Springer Press., pp. 27 - 52

Norris MD; Burkhart CA; Haber M; Gudkov AV; Nikiforov MA, 2013, 'Cell-Based Methods for the Identification of MYC-Inhibitory Small Molecules', in Soucek L; Sodir NM (ed.), The Myc Gene, Humana Press Inc, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18

Cheung L; Murray JE; Norris MD; Haber M, 2013, 'Oncogene and Cancer - From Bench to Clinic', in Siregar YE; norris (ed.), Oncogene and Cancer - From Bench to Clinic, Inst za onkologiju i radiol, pp. 437 - 454, http://dx.doi.org/10.5772/54813

Xue C; Gudkov A; Haber M; Norris MD, 2012, 'Small molecule drugs and targeted therapies for neuroblastoma', in Shimada H (ed.), Neuroblastoma - Present and Future, In Tech, Croatia, pp. 299 - 324, http://www.amazon.com/Neuroblastoma-Present-and-Future-ebook/dp/B00CBWQI92/ref=sr_1_1?ie=UTF8&qid=1366940364&sr=8-1&keywords=neuroblastoma+-+present+and+future#reader_B00CBWQI92

Fletcher JI; Haber M; Henderson M; Norris MD, 2012, 'Targeting Multidrug Resistance in Neuroblastoma', in Hayat MA (ed.), Pediatric Cancer Volume 1 Diagnosis, Therapy and Prognosis: Neuroblastoma, Springer, New York, USA, pp. 115 - 123, http://dx.doi.org/10.1007/978-94-007-2418-1_11

Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA, 2012, 'The Myc Gene: Methods and Protocols: Myc inhibitory molecules', in Methods in Molecular Biology, Humana Press

Haber M; Kavallaris M, 2000, 'Multidrug Resistance Genes in Neuroblastoma', in Neuroblastoma, Elsevier Science BV, Amsterdam, pp. 207 - 215

Journal articles

Nelson CB; Rogers S; Roychoudhury K; Tan YS; Atkinson CJ; Sobinoff AP; Tomlinson CG; Hsu A; Lu R; Dray E; Haber M; Fletcher JI; Cesare AJ; Hegde RS; Pickett HA, 2024, 'The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-45683-4

Hassan N; Yi H; Malik B; Gaspard-Boulinc LC; Samaraweera SEE; Casolari DA; Seneviratne JA; Balachandran A; Chew T; Duly A; Carter DRR; Cheung B; Norris M; Haber M; Kavallaris M; Marshall GM; Zhang XD; Liu T; Wang J; Liebermann DA; D'Andrea RJJ; Wang JY, 2024, 'Loss of stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML.', Blood, http://dx.doi.org/10.1182/blood.2024024072

Karsa M; Xiao L; Ronca E; Bongers A; Spurling D; Karsa A; Cantilena S; Mariana A; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Sutton R; Lock RB; Williams O; de Boer J; Haber M; Norris MD; Henderson MJ; Somers K, 2024, 'FDA-approved disulfiram as a novel treatment for aggressive leukemia', Journal of Molecular Medicine, 102, pp. 507 - 519, http://dx.doi.org/10.1007/s00109-023-02414-4

Hogarty MD; Ziegler DS; Franson A; Chi YY; Tsao-Wei D; Liu K; Vemu R; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer B; Balis FM; Groshen S; Norris MD; Haber M; Park JR; Matthay KK; Marachelian A, 2024, 'Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial', British Journal of Cancer, 130, pp. 788 - 797, http://dx.doi.org/10.1038/s41416-023-02525-2

Rouaen JR; Salerno A; Luciani F; Murray J; Shai-Hee T; Tedla N; Haber M; Trahair TN; Vittorio O, 2024, 'Abstract 2673: Copper chelation overcomes the immunosuppressive neuroblastoma microenvironment to potentiate anti-GD2 antibody therapy', Cancer Research, 84, pp. 2673 - 2673, http://dx.doi.org/10.1158/1538-7445.am2024-2673

Mayoh C; Gifford AJ; Terry R; Lau LMS; Wong M; Rao P; Shai-Hee T; Saletta F; Khuong-Quang DA; Qin V; Mateos MK; Meyran D; Miller KE; Yuksel A; Mould EVA; Bowen-James R; Govender D; Senapati A; Zhukova N; Omer N; Dholaria H; Alvaro F; Tapp H; Diamond Y; Pozza LD; Moore AS; Nicholls W; Gottardo NG; McCowage G; Hansford JR; Khaw SL; Wood PJ; Catchpoole D; Cottrell CE; Mardis ER; Marshall GM; Tyrrell V; Haber M; Ziegler DS; Vittorio O; Trapani JA; Cowley MJ; Neeson PJ; Ekert PG, 2023, 'A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer', Genome Medicine, 15, http://dx.doi.org/10.1186/s13073-023-01170-x

Murray J; Pandher R; Xiao L; Somers K; Brand J; Mosmann E; Alfred S; Kusuma F; Kearns A; Park JR; Marshall LV; Gorrini C; Chesler L; Hogarty MD; Pearson ADJ; Burns M; Fletcher JI; Ziegler D; Norris MD; Haber M, 2023, 'Abstract B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone', Molecular Cancer Therapeutics, 22, pp. B132 - B132, http://dx.doi.org/10.1158/1535-7163.targ-23-b132

Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D’Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA, 2023, 'Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes', Scientific Reports, 13, http://dx.doi.org/10.1038/s41598-023-30395-4

Wakefield CE; Hetherington K; Robertson EG; Donoghoe MW; Hunter JD; Vetsch J; Marron JM; Tucker KM; Marshall GM; Broom A; Haber M; Tyrrell V; Malkin D; Lau L; Mateos MK; O’Brien TA; Ziegler DS, 2023, 'Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives', British Journal of Cancer, 129, pp. 1634 - 1644, http://dx.doi.org/10.1038/s41416-023-02429-1

Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR, 2023, 'Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms242115571

Mayoh C; Mao J; Xie J; Tax G; Chow SO; Cadiz R; Pazaky K; Barahona P; Ajuyah P; Trebilcock P; Malquori A; Gunther K; Avila A; Yun DY; Alfred S; Gopalakrishnan A; Kamili A; Wong M; Cowley MJ; Jessop S; Lau LMS; Trahair TN; Ziegler DS; Fletcher JI; Gifford AJ; Tsoli M; Marshall GM; Haber M; Tyrrell V; Failes TW; Arndt GM; Lock RB; Ekert PG; M Dolman ME, 2023, 'High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer', Cancer Research, 83, pp. 2716 - 2732, http://dx.doi.org/10.1158/0008-5472.CAN-22-3702

Daly R; Hetherington K; Hazell E; Wadling BR; Tyrrell V; Tucker KM; Marshall GM; Ziegler DS; Lau LMS; Trahair TN; O’Brien TA; Collins K; Gifford AJ; Haber M; Pinese M; Malkin D; Cowley MJ; Karpelowsky J; Drew D; Jacobs C; Wakefield CE, 2023, 'Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial', Journal of Personalized Medicine, 13, http://dx.doi.org/10.3390/jpm13071033

Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M; Moles Meler E, 2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262

Hastings JF; Latham SL; Kamili A; Wheatley MS; Han JZR; Wong-Erasmus M; Phimmachanh M; Nobis M; Pantarelli C; Cadell AL; O’Donnell YEI; Leong KH; Lynn S; Geng FS; Cui L; Yan S; Achinger-Kawecka J; Stirzaker C; Norris MD; Haber M; Trahair TN; Speleman F; De Preter K; Cowley MJ; Bogdanovic O; Timpson P; Cox TR; Kolch W; Fletcher JI; Fey D; Croucher DR, 2023, 'Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.abp8314

Ballinger ML; Pattnaik S; Mundra PA; Zaheed M; Rath E; Priestley P; Baber J; Ray-Coquard I; Isambert N; Causeret S; van der Graaf WTA; Puri A; Duffaud F; Le Cesne A; Seddon B; Chandrasekar C; Schiffman JD; Brohl AS; James PA; Kurtz JE; Penel N; Myklebost O; Meza-Zepeda LA; Pickett H; Kansara M; Waddell N; Kondrashova O; Pearson JV; Barbour AP; Li S; Nguyen TL; Fatkin D; Graham RM; Giannoulatou E; Green MJ; Kaplan W; Ravishankar S; Copty J; Powell JE; Cuppen E; van Eijk K; Veldink J; Ahn JH; Kim JE; Lor Randall R; Tucker K; Judson I; Sarin R; Ludwig T; Genin E; Deleuze JF; Haber M; Marshall G; Cairns MJ; Blay JY; Thomas DM, 2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784

Liu T; Lee AEL; Porro A; Smith SA; Dwarte T; Liu PY; Iraci N; Sekyere E; Haber M; Norris MD; Diolaiti D; Della Valle G; Perini G; Marshall GM, 2022, 'Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis (vol 104, pg 18682, 2007)', PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 120, http://dx.doi.org/10.1073/pnas.2220015120

Novototskaya-Vlasova KA; Neznanov NS; Molodtsov I; Hall BM; Commane M; Gleiberman AS; Murray J; Haber M; Norris MD; Leonova KI; Gudkov AV, 2022, 'Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors', Proceedings of the National Academy of Sciences of the United States of America, 119, http://dx.doi.org/10.1073/pnas.2213146119

Tang TCY; Xu N; Nordon R; Haber M; Micklethwaite K; Dolnikov A, 2022, 'Donor T cells for CAR T cell therapy', Biomarker Research, 10, pp. 14, http://dx.doi.org/10.1186/s40364-022-00359-3

Hanssen KM; Wheatley MS; Yu DMT; Conseil G; Norris MD; Haber M; Cole SPC; Fletcher JI, 2022, 'GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators', FEBS Journal, 289, pp. 3854 - 3875, http://dx.doi.org/10.1111/febs.16374

Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K, 2022, 'The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression', Frontiers in Oncology, 12, pp. 863329, http://dx.doi.org/10.3389/fonc.2022.863329

Lau LMS; Mayoh C; Xie J; Barahona P; MacKenzie KL; Wong M; Kamili A; Tsoli M; Failes TW; Kumar A; Mould EVA; Gifford A; Chow SO; Pinese M; Fletcher JI; Arndt GM; Khuong-Quang DA; Wadham C; Batey D; Eden G; Trebilcock P; Joshi S; Alfred S; Gopalakrishnan A; Khan A; Grebert Wade D; Strong PA; Manouvrier E; Morgan LT; Span M; Lim JY; Cadiz R; Ung C; Thomas DM; Tucker KM; Warby M; McCowage GB; Dalla-Pozza L; Byrne JA; Saletta F; Fellowes A; Fox SB; Norris MD; Tyrrell V; Trahair TN; Lock RB; Cowley MJ; Ekert PG; Haber M; Ziegler DS; Marshall GM; Trahair T, 2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. e14608, http://dx.doi.org/10.15252/emmm.202114608

Gao J; Jung M; Williams RT; Hui D; Russell AJ; Naim AJ; Kamili A; Clifton M; Bongers A; Mayoh C; Ho G; Scott CL; Jessup W; Haber M; Norris MD; Henderson MJ, 2022, 'Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer', Cancers, 14, pp. 1878, http://dx.doi.org/10.3390/cancers14081878

Karsa M; Ronca E; Bongers A; Mariana A; Moles E; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Kavallaris M; Haber M; Norris MD; Henderson MJ; Xiao L; Somers K; Moles Meler E, 2022, 'Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia', Frontiers in Oncology, 11, pp. 779859, http://dx.doi.org/10.3389/fonc.2021.779859

Seneviratne JA; Carter DR; Mittra R; Gifford A; Kim PY; Luo JS; Mayoh C; Salib A; Rahmanto AS; Murray J; Cheng NC; Nagy Z; Wang Q; Kleynhans A; Tan O; Sutton SK; Xue C; Chung SA; Zhang Y; Sun C; Zhang L; Haber M; Norris MD; Fletcher JI; Liu T; Dilda PJ; Hogg PJ; Cheung BB; Marshall GM, 2022, 'Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma', International Journal of Cancer, 152, pp. 1399 - 1413, http://dx.doi.org/10.1002/ijc.34349

Segura MF; Soriano A; Roma J; Piskareva O; Jiménez C; Boloix A; Fletcher JI; Haber M; Gray JC; Cerdá-Alberich L; Martínez de Las Heras B; Cañete A; Gallego S; Moreno L, 2022, 'Methodological advances in the discovery of novel neuroblastoma therapeutics', Expert Opinion on Drug Discovery, 17, pp. 167 - 179, http://dx.doi.org/10.1080/17460441.2022.2002297

Khan A; Gamble LD; Upton DH; Ung C; Yu DMT; Ehteda A; Pandher R; Mayoh C; Hébert S; Jabado N; Kleinman CL; Burns MR; Norris MD; Haber M; Tsoli M; Ziegler DS, 2021, 'Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas', Nature Communications, 12, pp. 971, http://dx.doi.org/10.1038/s41467-021-20896-z

Fleuren EDG; Terry RL; Meyran D; Omer N; Trapani JA; Haber M; Neeson PJ; Ekert PG, 2021, 'Enhancing the potential of immunotherapy in paediatric sarcomas: Breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors', Biomedicines, 9, pp. 1798, http://dx.doi.org/10.3390/biomedicines9121798

Hanssen KM; Haber M; Fletcher JI, 2021, 'Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition', Drug Resistance Updates, 59, pp. 100795, http://dx.doi.org/10.1016/j.drup.2021.100795

Gifford AJ; Murray J; Fletcher JI; Marshall GM; Norris MD; Haber M, 2021, 'A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma', Current Protocols, 1, pp. e310, http://dx.doi.org/10.1002/cpz1.310

Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB, 2021, 'Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia', Leukemia, 35, pp. 3101 - 3112, http://dx.doi.org/10.1038/s41375-021-01248-8

Meyran D; Terry RL; Zhu JJ; Haber M; Ziegler DS; Ekert PG; Trapani JA; Darcy PK; Neeson PJ, 2021, 'Early-phenotype CAR-T cells for the treatment of pediatric cancers', Annals of Oncology, 32, pp. 1366 - 1380, http://dx.doi.org/10.1016/j.annonc.2021.07.018

Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG, 2021, 'Chimeric antigen receptor t cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma', Cancers, 13, pp. 4704, http://dx.doi.org/10.3390/cancers13184704

Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O’Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M, 2021, 'Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma', Clinical Cancer Research, 27, pp. 4338 - 4352, http://dx.doi.org/10.1158/1078-0432.CCR-20-2357

Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K, 2021, 'Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin', British Journal of Cancer, 125, pp. 55 - 64, http://dx.doi.org/10.1038/s41416-021-01332-x

Xiao L; Yeung H; Haber M; Norris MD; Somers K, 2021, 'Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors', Trends in Cancer, 7, pp. 751 - 777, http://dx.doi.org/10.1016/j.trecan.2021.05.002

Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS, 2021, 'Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG', Cell Reports, 35, pp. 108994, http://dx.doi.org/10.1016/j.celrep.2021.108994

Gamble LD; Purgato S; Henderson MJ; Di Giacomo S; Russell AJ; Pigini P; Murray J; Valli E; Milazzo G; Giorgi FM; Cowley M; Ashton LJ; Bhalshankar J; Schleiermacher G; Rihani A; Van Maerken T; Vandesompele J; Speleman F; Versteeg R; Koster J; Eggert A; Noguera R; Stallings RL; Tonini GP; Fong K; Vaksman Z; Diskin SJ; Maris JM; London WB; Marshall GM; Ziegler DS; Hogarty MD; Perini G; Norris MD; Haber M, 2021, 'A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma', Cancers, 13, pp. 1807, http://dx.doi.org/10.3390/cancers13081807

Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM, 2021, 'A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma', Oncogene, 40, pp. 2367 - 2381, http://dx.doi.org/10.1038/s41388-021-01712-w

Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY, 2021, 'The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma', Molecular Oncology, 15, pp. 1162 - 1179, http://dx.doi.org/10.1002/1878-0261.12906

Grohmann C; Walker F; Devlin M; Luo MX; Chüeh AC; Doherty J; Vaillant F; Ho GY; Wakefield MJ; Weeden CE; Kamili A; Murray J; Po’uha ST; Weinstock J; Kane SR; Faux MC; Broekhuizen E; Zheng Y; Shield-Artin K; Kershaw NJ; Tan CW; Witchard HM; Ebert G; Charman SA; Street I; Kavallaris M; Haber M; Fletcher JI; Asselin-Labat ML; Scott CL; Visvader JE; Lindeman GJ; Watson KG; Burgess AW; Lessene G, 2021, 'Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors', Cell Death and Disease, 12, pp. 268, http://dx.doi.org/10.1038/s41419-020-03269-0

Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044

Back to profile page